Nanomerics - Pharmaceutical Nanotechnology

Nanomerics is "switching on" drugs. Nanomerics uses leading know-how in pharmaceutical nanotechnology to overcome the limitations of current drugs to develop products that deliver patient benefit in areas of unmet medical need.

Nanomerics licenses North American rights to NM133

Nanomerics today announced that it has licensed the North American rights to NM133 for the treatment of dry eye to IACTA Pharmaceuticals.

iacta logoIACTA Pharmaceuticals, Inc., a privately held pharmaceutical company, has acquired the North American rights to develop and commercialize NM133, an investigational medicine designed to help treat dry eye.

Nanomerics to Attend Biotech Showcase in San Francisco - 9th - 11th January 2017

Nanomerics is pleased to announce that Nanomerics’ Chief Scientific Officer, Professor Ijeoma F. Uchegbu, will again be attending Biotech Showcase (co-located with the JP Morgan Healthcare Conference) in San Francisco, CA, USA from the 9th - 11th January 2017.  If you wish to meet with with Professor Uchegbu, please get in touch (Contact)  and we will arrange a meeting.

Nanomerics CSO Prof Uchegbu wins Innovative Science Award

At the recent annual International APS PharmSci conference organised by the Academy of Pharmaceutical Sciences, Professor Ijeoma Uchegbu was awarded the Innovative Science Award, sponsored by GSK for her work on translating science into practice.

New Publication Demonstrates the Utility of Nanomerics’ Molecular Envelope Technology (MET) in the Treatment of Experimental Brain Tumours

Nanomerics’ scientists have demonstrated that encapsulating chemotherapy drugs within Nanomerics’ MET nanoparticles diverts the drug from the bone marrow, while enabling higher levels of drug to access the brain.  Animals intravenously dosed with Nanomerics’ MET - lomustine formulations showed significantly improved survival rates when compared to the drug in solution and the effect of the drug on the bone marrow was comparable to the drug in solution.

Nanomerics' Oral Amphotericin B Promises Better Treatment for Millions has developed a nano-enabled orally active form of Amphotericin B which could provide improved access to efficacious therapy to millions of people affected by Leishmaniasis.

Nanomerics Announces Completion of Major Preclinical Toxicology Programme on its Molecular Envelope Technology

Nanomerics today announced the successful completion of a major preclinical toxicology programme on its Molecular Envelope Technology (MET), paving the way for the technology’s clinical testing.  Safety pharmacology, mutagenicity and a range of 28 day repeat dose Good Laboratory Practice (GLP) standard toxicology tests have been completed on two species (rodent and non-rodent).

Fighting Fit - Nanomerics featured in CBI Business Voice Publication

moleculesIn the October edition of the CBI's  online publication 'Business Voice' journalist Dan Jellinek looks at how leading UK innovators contribute to the expanding UK life science sector. Nanomerics' CEO Prof Andreas Schatzlein describes how support from the EPSRC,  the Wellcome Trust, and Innovate UK has helped Nanomerics to translate scientific research into medicines which bring important patient benefits.

Prof Martin Koltzenburg Joins Nanomerics Advisory Board

Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.  Professor Koltzenburg’s appointment will  support the clinical development of iNanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.

Subscribe to Nanomerics RSS
MET Fibrous Hydrogel